UCB SA (UCB.BR)
EUR 187.45
(0.83%)
EUR 187.45
(0.83%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.17 Billion EUR | 8.8% |
| 2022 | 2 Billion EUR | 132.67% |
| 2021 | 860 Million EUR | -58.75% |
| 2020 | 2.08 Billion EUR | 119.01% |
| 2019 | 952 Million EUR | 301.69% |
| 2018 | 237 Million EUR | -54.77% |
| 2017 | 524 Million EUR | -37.62% |
| 2016 | 840 Million EUR | -31.03% |
| 2015 | 1.21 Billion EUR | -24.49% |
| 2014 | 1.61 Billion EUR | -19.35% |
| 2013 | 2 Billion EUR | 13.06% |
| 2012 | 1.76 Billion EUR | 14.13% |
| 2011 | 1.55 Billion EUR | -1.4% |
| 2010 | 1.57 Billion EUR | -10.53% |
| 2009 | 1.75 Billion EUR | -28.29% |
| 2008 | 2.45 Billion EUR | 26.22% |
| 2007 | 1.94 Billion EUR | -9.3% |
| 2006 | 2.14 Billion EUR | 239.14% |
| 2005 | 631 Million EUR | -69.51% |
| 2004 | 2.06 Billion EUR | 4905.76% |
| 2003 | -43.06 Million EUR | 91.07% |
| 2002 | -482.37 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.41 Billion EUR | 0.0% |
| 2023 FY | 2.17 Billion EUR | 8.8% |
| 2023 Q2 | 2.43 Billion EUR | 0.0% |
| 2023 Q4 | 2.17 Billion EUR | 0.0% |
| 2022 FY | 2 Billion EUR | 132.67% |
| 2022 Q2 | 2.5 Billion EUR | 0.0% |
| 2022 Q4 | 2 Billion EUR | 0.0% |
| 2021 Q2 | 1.51 Billion EUR | 0.0% |
| 2021 Q4 | 860 Million EUR | 0.0% |
| 2021 FY | 860 Million EUR | -58.75% |
| 2020 Q4 | 2.08 Billion EUR | 0.0% |
| 2020 Q2 | 1.91 Billion EUR | 0.0% |
| 2020 FY | 2.08 Billion EUR | 119.01% |
| 2019 Q4 | 952 Million EUR | 0.0% |
| 2019 FY | 952 Million EUR | 301.69% |
| 2019 Q2 | 387 Million EUR | 0.0% |
| 2018 Q4 | 237 Million EUR | 0.0% |
| 2018 FY | 237 Million EUR | -54.77% |
| 2018 Q2 | 773 Million EUR | 0.0% |
| 2017 FY | 524 Million EUR | -37.62% |
| 2017 Q2 | 988 Million EUR | 0.0% |
| 2017 Q4 | 524 Million EUR | 0.0% |
| 2016 Q4 | 840 Million EUR | 0.0% |
| 2016 FY | 840 Million EUR | -31.03% |
| 2016 Q2 | 1.34 Billion EUR | 0.0% |
| 2015 Q4 | 923 Million EUR | 0.0% |
| 2015 Q2 | 1.81 Billion EUR | 0.0% |
| 2015 FY | 1.21 Billion EUR | -24.49% |
| 2014 Q2 | 1.73 Billion EUR | 0.0% |
| 2014 FY | 1.61 Billion EUR | -19.35% |
| 2014 Q4 | 1.61 Billion EUR | 0.0% |
| 2013 Q4 | 2.01 Billion EUR | 0.0% |
| 2013 FY | 2 Billion EUR | 13.06% |
| 2013 Q2 | 2.09 Billion EUR | 0.0% |
| 2012 Q2 | 1.76 Billion EUR | 0.0% |
| 2012 FY | 1.76 Billion EUR | 14.13% |
| 2012 Q4 | 1.76 Billion EUR | 0.0% |
| 2011 Q4 | 1.55 Billion EUR | 0.0% |
| 2011 Q2 | 1.42 Billion EUR | 0.0% |
| 2011 FY | 1.55 Billion EUR | -1.4% |
| 2010 FY | 1.57 Billion EUR | -10.53% |
| 2010 Q4 | 1.57 Billion EUR | 0.0% |
| 2010 Q2 | 1.87 Billion EUR | 0.0% |
| 2009 Q4 | 1.75 Billion EUR | 0.0% |
| 2009 FY | 1.75 Billion EUR | -28.29% |
| 2008 FY | 2.45 Billion EUR | 26.22% |
| 2007 FY | 1.94 Billion EUR | -9.3% |
| 2006 FY | 2.14 Billion EUR | 239.14% |
| 2005 FY | 631 Million EUR | -69.51% |
| 2004 FY | 2.06 Billion EUR | 4905.76% |
| 2003 FY | -43.06 Million EUR | 91.07% |
| 2002 FY | -482.37 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 305001.961% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 1208.012% |
| Adocia SA | 127 Thousand EUR | -1714073.228% |
| Aelis Farma SA | -16.19 Million EUR | 13544.911% |
| Biophytis S.A. | 2.7 Million EUR | -80440.141% |
| Advicenne S.A. | 12.17 Million EUR | -17780.903% |
| genOway Société anonyme | 2.97 Million EUR | -73126.461% |
| IntegraGen SA | -709.74 Thousand EUR | 306828.153% |
| Medesis Pharma S.A. | 1.15 Million EUR | -187862.459% |
| Neovacs S.A. | -237.08 Thousand EUR | 918328.33% |
| NFL Biosciences SA | -2.27 Million EUR | 95755.727% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -49871.204% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 262216.097% |
| Sensorion SA | 1.37 Million EUR | -157857.136% |
| Theranexus Société Anonyme | 2.44 Million EUR | -88969.638% |
| TME Pharma N.V. | -1.07 Million EUR | 201860.89% |
| Valbiotis SA | -18.13 Million EUR | 12101.764% |
| TheraVet SA | 12.78 Thousand EUR | -17027666.914% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -99762.385% |
| argenx SE | -1.83 Billion EUR | 218.532% |
| BioSenic S.A. | 28.04 Million EUR | -7662.801% |
| Celyad Oncology SA | -6.1 Million EUR | 35776.827% |
| DBV Technologies S.A. | -114.95 Million USD | 1993.77% |
| Galapagos NV | -157.2 Million EUR | 1484.798% |
| Genfit S.A. | -7.61 Million EUR | 28703.337% |
| GeNeuro SA | 5.91 Million EUR | -36733.378% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 8769.162% |
| Innate Pharma S.A. | -30.71 Million EUR | 7188.434% |
| Inventiva S.A. | 10.48 Million EUR | -20655.077% |
| MaaT Pharma SA | -10.2 Million EUR | 21432.68% |
| MedinCell S.A. | 39.5 Million EUR | -5411.253% |
| Nanobiotix S.A. | -24.71 Million EUR | 8907.347% |
| Onward Medical N.V. | -12.89 Million EUR | 16983.822% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -152102.213% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | -7924.623% |
| Oxurion NV | 10.71 Million EUR | -20226.797% |
| Pharming Group N.V. | 99.4 Million EUR | -2090.105% |
| Poxel S.A. | 44.55 Million EUR | -4785.657% |
| GenSight Biologics S.A. | 16.29 Million EUR | -13260.746% |
| Transgene SA | -14.4 Million EUR | 15208.613% |
| Financière de Tubize SA | 78.62 Million EUR | -2668.834% |
| Valneva SE | 82.73 Million EUR | -2531.261% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 11852.321% |